Edition:
United States

Jaguar Health Inc (JAGX.OQ)

JAGX.OQ on NASDAQ Stock Exchange Capital Market

0.15USD
16 Feb 2018
Change (% chg)

$0.01 (+8.93%)
Prev Close
$0.14
Open
$0.14
Day's High
$0.15
Day's Low
$0.14
Volume
1,256,298
Avg. Vol
664,410
52-wk High
$1.52
52-wk Low
$0.11

Latest Key Developments (Source: Significant Developments)

Jaguar Health Says Unit Entered Amendment To Note Purchase Agreement
Tuesday, 2 Jan 2018 04:44pm EST 

Jan 2 (Reuters) - Jaguar Health Inc ::JAGUAR HEALTH - ON DEC 29, 2017, UNIT ENTERED AMENDMENT TO NOTE PURCHASE AGREEMENT & NOTES WITH EACH OF PURCHASERS PARTY TO AGREEMENT DATED MARCH 1, 2017.JAGUAR HEALTH - ITS UNIT AMENDED ORIGINAL ISSUE DISCOUNT EXCHANGEABLE PROMISSORY NOTES PREVIOUSLY ISSUED TO PURCHASERS ON MARCH 1, 2017 & APRIL 27, 2017.JAGUAR HEALTH SAYS AMENDMENT LOWERS PRICE AT WHICH NOTES ARE EXCHANGEABLE FOR SHARES OF CO'S COMMON STOCK FROM $0.56/SHARE TO $0.20/SHARE - SEC FILING.JAGUAR HEALTH - AMENDMENT EXTENDS MATURITY DATE OF FIRST TRANCHE NOTES FROM DEC 1, 2017 TO FEB 15 & SECOND TRANCHE NOTES FROM JAN 27 TO APRIL 1.  Full Article

Jaguar Health ‍Enters Collaboration Agreement With SEED For Equilevia​
Thursday, 14 Dec 2017 10:09am EST 

Dec 14 (Reuters) - Jaguar Health Inc ::JAGUAR HEALTH INC - ‍ENTERED COLLABORATION AGREEMENT WITH SEED MENA BUSINESSMEN SERVICES FOR EQUILEVIA​.JAGUAR HEALTH- AS PER TERMS OF DEAL, CO WILL PAY SEED ONGOING PERCENTAGE OF REVENUE GENERATED FROM ANY CLIENTS OR PARTNERS INTRODUCED TO CO BY SEED.JAGUAR HEALTH INC - ‍ ACCORDING TO TERMS OF AGREEMENT, AGREED-UPON REVENUE PERCENTAGE INCREASES AFTER FIRST ONE-MILLION DOLLARS OF REVENUE​.  Full Article

Jaguar Health enters share purchase agreement
Monday, 27 Nov 2017 09:00am EST 

Nov 27 (Reuters) - Jaguar Health Inc ::JAGUAR HEALTH ENTERS SHARE PURCHASE AGREEMENT FOR 2 MILLION SHARES AND COMMON STOCK PURCHASE AGREEMENT RELATING TO A 10 MILLION SHARE EQUITY LINE OFFERING WITH L2 CAPITAL, LLC.JAGUAR HEALTH-ON NOV 24,CO ENTERED SHARE PURCHASE AGREEMENT WITH L2 CAPITAL AFTER WHICH CO SOLD 2 MILLION SHARES OF VOTING COMMON STOCK AT $0.25 PER SHARE ​.  Full Article

Jaguar Health ‍signs non-binding term sheet to issue note to Iliad Research
Wednesday, 8 Nov 2017 07:30am EST 

Nov 8 (Reuters) - Jaguar Health Inc :Jaguar health enters non-binding agreement of terms to issue a secured convertible note to iliad research and trading, l.p. (an affiliate of chicago venture partners, l.p.), as jaguar expands commercial efforts for mytesi.Jaguar health inc - ‍signed a non-binding term sheet to issue to iliad research and trading, l.p. Note of $1,375,000 for purchase price of $1,100,000​.Jaguar health inc - ‍note will bear interest at rate of 8.0% per annum, with a fixed conversion price of $0.52/share​.Jaguar health inc - ‍note will be due nine months after its issue date​.  Full Article

Jaguar Health files for resale or other disposition of up to 36 million shares of co
Friday, 20 Oct 2017 04:46pm EDT 

Oct 20 (Reuters) - Jaguar Health Inc ::Jaguar Health files for resale or other disposition of up to 36 million shares of co by the selling shareholders ‍​.  Full Article

Jaguar Health prices $4.25 million public offering of common stock
Friday, 29 Sep 2017 01:24pm EDT 

Sept 29 (Reuters) - Jaguar Health Inc :Jaguar health prices $4.25 million public offering of common stock.Says public offering of 21.3 million shares priced at $0.20 per share.  Full Article

Jaguar subsidiary Napo and Glenmark pharma sign agreement returning key rights in 141 countries to Napo
Monday, 25 Sep 2017 09:00am EDT 

Sept 25 (Reuters) - Glenmark Pharmaceuticals Ltd :Jaguar subsidiary Napo Pharmaceuticals and Glenmark Pharmaceuticals sign agreement returning key rights in 141 countries to Napo, solidifying Jaguar’s global commercial control of Mytesi (Crofelemer), Jaguar’s fda-approved human drug.Jaguar Health- Glenmark will continue to serve as CGMP-compliant commercial manufacturer of Crofelemer for Jaguar and Napo at its FDA-approved facilities in India.Jaguar Health- agreement also provides Napo with commercial rights to existing regulatory approvals for Crofelemer in Brazil, Ecuador, Zimbabwe & Botswana.  Full Article

Jaguar Health says FDA indicates co's Canalevia drug qualifies as “minor use” for exercise-induced diarrhea in dogs
Wednesday, 20 Sep 2017 09:00am EDT 

Sept 20 (Reuters) - Jaguar Health Inc ::FDA indicates that jaguar’s Canalevia drug product candidate qualifies as “minor use” for Exercise-Induced Diarrhea (EID) in dogs, rendering Canalevia eligible for conditional approval for this indication.Jaguar Health Inc - expects to conduct commercial launch of Canalevia in first half of 2018 for EID and CID in dogs.  Full Article

Jaguar Health proposes public offering of common stock
Monday, 18 Sep 2017 08:16am EDT 

Sept 18 (Reuters) - Jaguar Health Inc :Jaguar Health announces proposed public offering of common stock.Jaguar Health - intends to use proceeds from offering for commercialization of Mytesi-an FDA-approved human prescription drug product of co's unit​.  Full Article

Jaguar Health files for mixed shelf of up to $60 mln‍​
Tuesday, 29 Aug 2017 05:41pm EDT 

Aug 29 (Reuters) - Jaguar Health Inc ::Jaguar Health Inc files for mixed shelf of up to $60 million - sec filing‍​.Says ‍​in addition, selling shareholders may sell up to 6.9 million shares of co's common stock.  Full Article

BRIEF-Jaguar Health Files For Resale Or Other Disposition Of Up To 6.02 Mln Shares Of Voting Common Stock

* JAGUAR HEALTH INC FILES FOR RESALE OR OTHER DISPOSITION OF UP TO 6.02 MILLION SHARES OF VOTING COMMON STOCK - SEC FILING Source text: [http://bit.ly/2BJoioW] Further company coverage: